Trichostatin A (TSA)

製品コードS1045

Trichostatin A (TSA)化学構造

分子量(MW):302.4

Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。

サイズ 価格 在庫  
USD 408 あり
USD 311 あり
USD 563 あり
USD 1096 あり

カスタマーフィードバック(5)

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。
ターゲット
HDAC [1]
(Cell-free assay)
~1.8 nM
体外試験

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NIXUV|ZHfW6ldHnvckBCe3OjeR?= MlTxNE44|ryP MlrJNlRp M2WyTIV1cGGwb3y= NIj5XHdmdmijbnPld{BGVmGFIHHj[ZR6dGG2aX;uJIFv\CCrbnPy[YF{\XNiRV7hR{Bi[nWwZHHuZ4UhcW5idHjlJJRwfGGuIHPlcIwhdHm|YYTlJIFv\CCjdDD0bIUh[2WubDDzeZJn[WOn Mon6NlU4QDdyN{m=
TE13 M{exUGZ2dmO2aX;uJGF{e2G7 MnP2NE4{|ryP NFrFZ48zPGh? NFX1S212eC2{ZXf1cIF1\XNiUlHTV2Y2SSCuZY\lcC=> NYPvOVQ4OjV3N{m2OlU>
TE13 MWrBdI9xfG:|aYOgRZN{[Xl? M3LU[|AvO87:TR?= NEHmUZozPGh? NFfxNYtqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w NV3wNIROOjV3N{m2OlU>
MEFs NVLKdWhMTnWwY4Tpc44hSXO|YYm= MWO1{txO M4\LNlE3cA>? NXW1TIVQcW6lcnXhd4V{KHSqZTDFVGVEKGG2dHHjbI1mdnRuIGTpdkBl\WyrdnXyfUBidmRidHjlJIVn\mmlaXXuZ5khd2ZicHXk[ZN1[WxiZn;ycYF1cW:w MXWyOVQ5OjZ|NB?=
SW480  MmixSpVv[3Srb36gRZN{[Xl? NHHISY8xNjIQvF2= MkPMOFhp MkXaSG1UVw>? MlvjdoV3\XK|ZYOgSW1V Mkf6NlU1OzR7OUe=
PC3  NFn2U5VHfW6ldHnvckBCe3OjeR?= NHvLemsxNjIQvF2= MYW0PIg> NVfne5A6TE2VTx?= NHfiOXlz\X[ncoPld{BGVVR? MmLUNlU1OzR7OUe=
SW480  NX7kdINUTnWwY4Tpc44hSXO|YYm= NEfzNmIxNjIQvF2= M{nOVFQ5cA>? M2\6cWROW09? MoLGZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M{OyfFI2PDN2OUm3
PC3  MWXGeY5kfGmxbjDBd5NigQ>? NY\kUXFTOC5zzszN MmXwOFhp NETaNXpFVVOR Mn6wZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w M4L3WVI2PDN2OUm3
SW480  NEn6VIdHfW6ldHnvckBCe3OjeR?= MlT2NE4y|ryP Ml;3OFhp MWPEUXNQ MofObY5lfWOnczDpcoNz\WG|ZTDv[kBJTEGFMTDhcoQhUESDQ{Kgc44hW2y3ZzDn[Y5meyCycn;tc5Rmeg>? M4fsTVI2PDN2OUm3
PC3  NXL4eIpvTnWwY4Tpc44hSXO|YYm= MnTzNE4y|ryP NInYSJM1QGh? M2\F[GROW09? M4HXXolv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? NH7DOHgzPTR|NEm5Oy=>
A431 NGLqPGJCeG:ydH;zbZMhSXO|YYm= M4DIVVIwOTBxNUCvNVAxdk1? MmC3OFhp NV7VOXdkTE2VTx?= M3\abIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?= MW[yOVM4OTB4OR?=
A431 M1X6SWZ2dmO2aX;uJGF{e2G7 M1rR[|Uxdk1? NYK2[oo3Oi94L{GyM|I1cA>? M{LrZmROW09? NUD1NGVR[WO2aY\heIV{KHB{MTDhcoQhcW6qaXLpeJMhSVSIMzDlfJBz\XO|aX;u M4C0d|I2OzdzME[5
MDA-MB-231 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDiNE03ODCwTR?= NWrk[GJGOjSq Mkm4SG1UVw>? MWjJR|UxKG:oIEGwNI5O Ml;aNlUyQTJ5MkG=
MCF7 NEDUPJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTwWXNVOC14MEDuUS=> NV3oTm9UOjSq M4[4RWROW09? NVzTNYROUUN3MDDv[kA4PW6P MV:yOVE6Ojd{MR?=
SKOV-3 NGTSSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL3WoMyOS1zMN88US=> NIHWZXIzPGh? NIX3SI9FVVOR NGjCeVlKSzVyIH;mJFUvPs7:TR?= MWKyOVE3QTR7MR?=
A549 NYLCTGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXmNU0yOM7:TR?= M1q3c|I1cA>? NG[3e5pFVVOR NH\D[YNKSzVyIH;mJFMvOs7:TR?= M1LRc|I2OTZ7NEmx
SKOV-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj3NE4yNTIQvF2= MV:0PIg> NU\ubFdGTE2VTx?= NEjHWXhKSzVyIH;mJFAvP87:TR?= M1v1W|I2OTZ7NEmx
A549 M2Dm[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVi3N4pZOC5zLUJOwG0> M33vdVQ5cA>? M4L4dGROW09? NH60N|FKSzVyIH;mJFAvOjkQvF2= NIfkbZYzPTF4OUS5NS=>
SKOV-3 NF\keGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\VVXUxNjBzLUCuPe69VQ>? M37YflczcA>? NG\tPJFFVVOR NH;SbJhKSzVyIH;mJFAvOzMQvF2= NIjvS4QzPTF4OUS5NS=>
A549 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H6T|AvODFvMD65{txO MUO3Nog> MmLvSG1UVw>? MXHJR|UxKG:oIECuNFbPxE1? M{TzR|I2OTZ7NEmx
HeLa NXvlXIxbTnWwY4Tpc44hSXO|YYm= Mn:0NlUxdk1? MlPCNVZp NEfHZ3pFVVOR M3;zdIlv[3KnYYPld{BEYVBzQUGgcXJPSSCneIDy[ZN{cW:wwrC= NV[2XYhOOjVzMU[2PFg>
CNE2 M17YfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX1blRmOTByLU[wNI5O NX7qSVNNOjRxNEivO|Jp NHXjdnJqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M4C2dVI1QTZ7OUCx
PC3 NI\4NnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HFTFExOC1zMECwcm0> MYiyOIg> MX;JR|UxKG:oIEOwNI5O MXyyOFg2PDZ3OB?=
LNCaP NI\EU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnmRVd2OTByLUGwNFBvVQ>? MXuyOIg> M4n3bGlEPTBib3[gN|Axdk1? M13OS|I1QDV2NkW4
HeLa  MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDL[XAz|ryP M3XKc|Q5cA>? NFTDeGtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NV7sd3hZOjR6NE[xN|U>
HMEC-1  M4DtUGZ2dmO2aX;uJGF{e2G7 NFfRZYQ{ODCwTR?= M1\lVFI1cA>? NW[xZYREcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? MUSyOFcyODZ|MR?=
HeLa NWHwTJNRTnWwY4Tpc44hSXO|YYm= MYOxcW0> MX:wMlVp NXSzUlFS[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5 MWiyOFcxPzR5NB?=
ACP02 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXMU2wzPTBxM{WwM|UxOG6P NYXQWXZsOjSq M2PMbYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NILZTnIzPDZ4OEW0Oy=>
ACP03 NH7LdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37mW|I2OC9|NUCvOVAxdk1? MWCyOIg> MmPH[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MYqyOFY3QDV2Nx?=
U87 GBM MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TYZ|ExOC9|MECvOVAxKG6P NH3pO3U4OiCq NXXxXIE4OTByJTDleIhidm:u MlfDdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl M4P4WlI1PDZ2OESx
U87 GBM NGLjOFZHfW6ldHnvckBCe3OjeR?= MVWxNFAwPTByIF7t M3nQclQ5KGh? NUK5cpNVOTByJTDleIhidm:u MnfJTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 NXrndm9yOjR2NkS4OFE>
RPE MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXSwMlIwOC52L{CuPE8yKM7:TR?= MlX0NlQwPDhxN{KgbC=> MkPsSG1UVw>? M1Hv[4lvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 M4rqXVI1PDV4NkCy
HT29  NWnUTWI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrkNVgxKG6P M2r0S|czKGh? NX\mNZd4UUN3MDDv[kAyQDBibl2= NXPiS21JOjR|NkiyOlU>
hMSCs NFTzN3dHfW6ldHnvckBCe3OjeR?= NITWRVY3NjJ3IH7N M1fBXVI1KGh? Mk\DSG1UVw>? MYDzeIFjcWyrenXzJGhqe3SxbnWgRYNmfHmuYYTpc44h[W6mIITo[UBGgHC{ZYPzbY9vKG:oIGDseZJqeG:2ZX70JGdmdmW| MY[yOFMyOjN3Nh?=
Huh7  MVjGeY5kfGmxbjDBd5NigQ>? MVmwMlEwOC53L{GuNEDPxE1? NHHXfYMzPGh? NIPVZVl{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36= M{fRXFI1OjZ7Nkey
SKOV3 M4q2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LER|AvODVvMjFOwG0> NVzqc5RROTBxMkSvOFghcA>? MmHjSG1UVw>? NF3nV|lu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NV;BO4FsOjR{MkO4NFE>
A2780 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTZVGlWOC5yNT2yJO69VQ>? NILKOGoyOC9{ND:0PEBp NGXKOmtFVVOR MX7t[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MUiyOFIzOzhyMR?=
SRA01/04  M{LFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvFXWt1OC5{IN88US=> NY\zNmpjPDhiaB?= M3HMdGROW09? NGPQXlZ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? MVuyOFE2Pzh5OB?=
HLEB3 M2\4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYCwMlIh|ryP Mn\pOFghcA>? NHvFVo9FVVOR NXH0[5Y5e3WycILld5NmeyClZXzsJJBzd2yrZnXyZZRqd25idHjyc5VocCC|dYDwdoV{e2mwZzD0bIUhWEl|Sz;Bb5QtKHB|OF3BVGsh[W6mIFXST|EwOiC|aXfuZYxqdmdicHH0bJdigXN? NYLtTHVHOjRzNUe4O|g>
SRA01/04  NXXmXZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILXfncxNjRxMD64JO69VQ>? MUK0PEBp MVLEUXNQ M4\pXIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIS1eJgzPDF3N{i3PC=>
HLEB3 MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3hNE41NzBwODFOwG0> NWDyeJZwPDhiaB?= MX;EUXNQ MofQbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M3G0O|I1OTV5OEe4
HCT116 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PzdFAvOiEQvF2= M3jURVEzKGh? M1zQU4VvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgdoFlcWG2aX;u NFOydoszPDF{MkKzNS=>
CA46 NFLxRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fpRVMwPi9zMj:yOE81QCCwTR?= MmLVOFghcA>? NXW1fGozcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= NVvXbJRYOjRyNkS5OVE>
PMNs MnTXSpVv[3Srb36gRZN{[Xl? M{L6T|MxKG6P MoWxOFghcA>? NYTWcVdZcW6qaXLpeJMh\W[oZYLvZ5l1d3OrczygTGRCSyCjY4Tpeol1gSCjbnSgVoFkKGGldHn2bZR6 Mn;DNlM6QDh4MUe=
H1299 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXrNeKh|ryPwrC= NXL1VFM1OjRxNEivO|IhcA>? M3e2d4V1cGGwb3y= MmnubY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp MViyN|kyPjZyOR?=
A549 NHz3eo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1njXVAvOjVxMD61M|Eh|ryP NFG5ZY8zPC92OD:3NkBp NHzxZWNmfGijbn;s M{HSXYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M1r5RlI{QDZ5OUmx
H1299 NEXHWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXkNE4zPS9yLkWvNUDPxE1? M4\sR|I1NzR6L{eyJIg> NHXleY9mfGijbn;s MmeybY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnuJINwdmOnboTyZZRqd25iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NYHCNWFWOjN6Nke5PVE>
A549 NYnpO4x6SXCxcITvd4l{KEG|c3H5 MXiwMlUwOSEQvF2= NX;ZWWpwPDhiaB?= NVfKNFBS\XSqYX7vcC=> MYTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NVfr[4xEOjN6Nke5PVE>
H1299 NImwe4pCeG:ydH;zbZMhSXO|YYm= NVn1T5A5OC53L{Gg{txO MXy0PEBp MVXleIhidm:u Mnj0bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlfnNlM5Pjd7OUG=
SUM149PT M4TPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\WTmEzNzdwNT:xNEDPxE1? MmCxOFghcA>? NV;jWoJNTE2VTx?= M3rL[4lv\HWlZYOgZ4VtdCCmZXH0bEBifCB{IN88UUBqdnOnboPpeIl3\Wy7 NHzkVoMzOzd7Mk[zPC=>
SUM190PT NYjRemFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUC1NE8yODBxMkWwJI5O MX60PEBp NY\CfpVTTE2VTx?= MkS3bY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6 NGrRbYszOzd7Mk[zPC=>
HCT1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXjb2xFOC5{L{GuNE82NjBizszN MWqxNk8zPC9|Nj:0PEBp NEnKcIFqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MlTONlM4PzByMEC=
Lovo NEnlRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[zUlAvOi9zLkCvOU4xKM7:TR?= MVGxNk8zPC9|Nj:0PEBp NGeyNohqdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M{C4dlI{PzdyMECw
AGS M4\RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlizNE4xOTVvMTFOwG0> NVPYTZNFPzJiaB?= MXzpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MoTHNlM4PDVyMkS=
Huh7 M1PXSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\XNUDPxE1? M{XtR|I1KGh? MlvTSG1UVw>? NE\6ZVhz\WS3Y3XzJIFjd3W2IEKwKUB3cWGkaXzpeJnDqA>? MWOyN|Y1Ozl|Mx?=
ECC1 MnHGSpVv[3Srb36gRZN{[Xl? NVG0WpB4PTByIH7N NWr5cXR[PSCm NUKxdFNOTE2VTx?= MV7pcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? NFzwdXgzOzV|MEe2PS=>
HEC1A NXnlSHhsTnWwY4Tpc44hSXO|YYm= NFTEVIY2ODBibl2= MVm1JIQ> MYjEUXNQ M4HDTYlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF M4f5NVI{PTNyN{[5
EN1 NXf0cGFoTnWwY4Tpc44hSXO|YYm= MXO1NFAhdk1? MUi1JIQ> MkHVSG1UVw>? M3LsTIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF MXKyN|U{ODd4OR?=
MFE296 M3PzU2Z2dmO2aX;uJGF{e2G7 NUTsOYtYPTByIH7N NXHDS2w4PSCm NWHFOlVQTE2VTx?= NWnyeYlJcW6mdXPld{BNOUODTdMg[ZhxemW|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO= NXnSe4p7OjN3M{C3Olk>
HASMCs MULGeY5kfGmxbjDBd5NigQ>? NHHwVW8xNTVyMDDuUS=> MXe2JIQ> M2G3bIRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 MmP1NlM2OTh2Nke=
U373 M{HLcmZ2dmO2aX;uJGF{e2G7 MoPJNE4zPS9yLkWvNUDPxE1? NGDp[nUzPCCq MnLKbY5kemWjc3XzJHBTNUJiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1RZpi\EN? MUOyN|Q4PDF5MR?=
ARN8  MkXjSpVv[3Srb36gRZN{[Xl? NED4[3ExNjB3LUKg{txO NUnzcFY4OjRiaB?= NIPKe4Nz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? NFrqXVAzOzR5MEW0NC=>
MCF7 M17o[GZ2dmO2aX;uJGF{e2G7 MXGwMlA2NTJizszN M2HlTVI1KGh? NHvmSJNz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? MVeyN|Q4ODV2MB?=
H1299  MnPaSpVv[3Srb36gRZN{[Xl? MWiwMlM{6oDVMdMgxtVO NWHVSJJuOjRxNEigbC=> M3n5V2ROW09? MVXpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 NUDmZlBzOjN2NkG5O|U>
H1299 NUjRdXFwTnWwY4Tpc44hSXO|YYm= NYPSenFbOC53IN88US=> NHPTOGI1QCCq MmDCSG1UVw>? MoPQbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NFHsNo4zOzR4MUm3OS=>
H1299 NYnWTlNQTnWwY4Tpc44hSXO|YYm= M1ywXlAvPSEQvF2= MVu0PEBp M{XvWGROW09? M4W0[YlvcGmkaYTzJJRp\SCrbo\hd4l3\W6nc4RCpEBkd22kaX7lJJdqfGhic3nsbYJqdmmw MYKyN|Q3OTl5NR?=
MG-63  NGLPeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz6NE4{KM7:TR?= NV\lc486OTJvOU[gbC=> M3z3[GROW09? M1:xZ4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= M4fFPFI{PDVzOEG3
LM8 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2H3VFAvOyEQvF2= MkP2NVIuQTZiaB?= NIrGT2dFVVOR M1zPXIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDjc{11emWjdH3lcpQhf2m2aDDt[ZRnd3KvaX6= MnjFNlM1PTF6MUe=
K562 Mne4SpVv[3Srb36gRZN{[Xl? NEi5eI0xNjVizszN Mo\wNlQhcA>? MkHy[ZRp[W6xbB?= MULk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NIK0U4szOzR|MEm1Oy=>
HEL MnXVSpVv[3Srb36gRZN{[Xl? M{LOO|AvPSEQvF2= NEC3RVUzPCCq M1LVc4V1cGGwb3y= NIrvXYdl\WO{ZXHz[ZMhfGinIHXufplu\SCjY4Tpeol1gSCxZjDISGFEeyClbz30doVifG2nboSge4l1cCCldYLjeY1qdg>? M3jUcFI{PDNyOUW3
HL60 NFnVNnpCeG:ydH;zbZMhSXO|YYm= Mli2NUDPxE1? NGP3b4MzPCCq M2XH[4lv\HWlZYRCpINmdGxiZHXheIg> NFv5UmszOzRyMEWxPS=>
KG1 MVvBdI9xfG:|aYOgRZN{[Xl? NVLZSXo4OSEQvF2= M2\HN|I1KGh? NFK1N2RqdmS3Y3XzxsBk\WyuIHTlZZRp NXL2fld[OjN2MEC1NVk>
Kazumi MVzBdI9xfG:|aYOgRZN{[Xl? MkfINUDPxE1? NEDUSYkzPCCq NG[2WG1qdmS3Y3XzxsBk\WyuIHTlZZRp NHfQUHozOzRyMEWxPS=>
K562 MVTBdI9xfG:|aYOgRZN{[Xl? MlnaNUDPxE1? M13uflI1KGh? MWjpcoR2[2W|wrDj[YxtKGSnYYTo NVHQN2hIOjN2MEC1NVk>
THP1 NGi4SpNCeG:ydH;zbZMhSXO|YYm= M2DCeFEh|ryP NVLmZ4VtOjRiaB?= MnrtbY5lfWOnc9MgZ4VtdCCmZXH0bC=> NFf2Zo0zOzRyMEWxPS=>
SH-SY5Y NFzEXmJHfW6ldHnvckBCe3OjeR?= M4L5flI2OCCwTR?= M3jyUVE3KGh? MmXjZ4hidmenczDlfJBz\XO|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m|LDD1dJRic2ViYX7kJIVn\my3eB?= NHXqR2czOzN{NkSyNi=>
HEK293 M1z1SmZ2dmO2aX;uJGF{e2G7 NV\SVWZPOSEEtV5CpC=> MoqzNVghcMLi MkHwbY5pcWKrdIOgeIhmKGujbHnybY4uPy2vZXTpZZRm\CC{ZXPyeYl1dWWwdDDv[kB{gW6yaHnsbY4uOSCjZ3fy[YdifGW|IHnueI8h[WepcnXzc41mew>? M3e4OVI{Ojh2OES4
HTK NF\w[o1HfW6ldHnvckBCe3OjeR?= NVTSeZJNPDByIH7N MlPpO|IhcA>? NHjGVGtqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v MoXoNlMzQDRyMEK=
HTK M{jiWmZ2dmO2aX;uJGF{e2G7 MXKxNFAuQDBybl2= NEXTOnQ4OiCq NULHcGtj[myxY3vzJHRITi4QsvMAl2lv\HWlZXSgVm9UKGGwZDDINm8zyqCDY3P1cZVt[XSrb36= Mn3UNlMzQDRyMEK=
Caco-2  NYDCcY41TnWwY4Tpc44hSXO|YYm= MoXyNUDDvU4EoB?= NVLoTW51OjRiaB?= M{KzeoRm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MnrmNlMyQTVyN{C=
HeLa MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLVTIpsOTByIH7N NUnKWHpsOjRiaB?= NWHoRnZKTE2VTx?= M3HaWmlEPTBib3[gNVAxdk1? NX2wZXo4OjNzNkW3OFg>
HeLa MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjFbVEzPDBibl2= MmnhOFghcA>? M3m5PGROW09? NX7m[pJYUUN3MDDv[kA1OG6P M{fzOFI{OTZ3N{S4
HeLa NFXKVXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmewNlAhdk1? MknRO|IhcA>? MlfJSG1UVw>? NWHmeI5uUUN3MDDv[kAzOG6P M3;WcVI{OTZ3N{S4
HeLa NGLR[FVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\tNVAwOzBxNUCgcm0> M2LnblczKGh? M{PrcGROW09? NVflRppVcW6lcnXhd4V{KHSqZTDueY1j\XJib3[gUW1RKCkQlN8ocUkhdG:|czDj[YxteyCmb4PlJIRmeGWwZHXueIx6 M2DhUFI{OTZ3N{S4
MDA-MB-231 NHqzXIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1viTFI2NTRyMDDuUS=> NGfzVo41QCCq NYnIZWpnUUN3MDDv[kAzPjNwMn7NxsA> MXqyN|A2PTF7OB?=
MCF-7  M33V[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PBOVI2NTRyMDDuUS=> M{TBdFQ5KGh? MV\JR|UxKG:oIEKyNE41dk1? MViyN|A2PTF7OB?=
ECC-1  NH;WWopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jo[|ExOCCwTR?= MYSyOEBp M3y1bYV1cGGwb3y= NXrrVFlscW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{Wl M2PkWVI{ODJ6OECz
HEC-1A M1Lze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjad5IyODBibl2= NV7aZWNLOjRiaB?= MXnleIhidm:u Ml\PbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzln MonCNlMxOjh6MEO=
NHAC-kn NWD6O2xXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn6ToIyOC9zMECvOVAxKG6P M1;0[|EzKGh? M3S4VmROW09? MWfJR|UxKG:oIEWwNI5O MnnrNlMxOTd6N{G=
A549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnOTnVIOjVyIH7N MU[2MVczKGh? NYW5Rm82TE2VTx?= MlnqZ4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> NHniT|EzOjl7NEe4NC=>
MG-63 M2DMR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHYN|AxKG6P MY[xNkBp NGnCVpJFVVOR M{XUd4lvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? NH7ZOGozOjd7OUOzPC=>
MG-63 M4\lOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPWN|AxKG6P NYPiNphGOjRiaB?= NUXtO3JvTE2VTx?= NF[0Z3RqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn MlrINlI4QTl|M{i=
MG-63 M2K3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojqN|AxKG6P M13oTVQ5KGh? MmHTSG1UVw>? NUfLS5JRcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDV4JR?= MVGyNlc6QTN|OB?=
HL60  NFrmdpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjPV|lUOTVyLUO1NEBvVQ>? MWGyOEBp NIqyNGhqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O MVyyNlc2Ozd|OR?=
U937 NXjGTXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxOVAuOzVyIH7N NIHtc4EzPCCq Ml[xbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> MmnFNlI4PTN5M{m=
SCC-6 M1\1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;kb3QzODBvM{KwNEBvVQ>? MkHmNVIwOjRxNEigbC=> NILvdJBFVVOR NYnPd5k2cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy M{L6W|IzPTV{M{Kx
U87  NIjYeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rBRVExOC1|MECgcoc> NIi2[owzPCCq MU\pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO|ImKCCjdDCyNFBv\w>? NV7OUZpSOjJ{N{C4OFk>
K562 MV7GeY5kfGmxbjDBd5NigQ>? NGrWOWYyKM7:TR?= MofwNVIhcA>? NV;QV5ZlTE2VTx?= MVXlcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MkPPNlIyPzlzOUi=
Reh MYnGeY5kfGmxbjDBd5NigQ>? M4fIUFAvOy9zIN88US=> MlvaNVIhcA>? M3q2SWROW09? MY\lcohidmOnczD0bIUh\XiycnXzd4lwdiCxZjDSWW5ZOyCrbnT1Z4VlKGK7IEWtZZpiNUOmUh?= MoPxNlIyPzlzOUi=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • 濃度: Dissolved in absolute ethanol, final concentrations ~10 μM
  • 反応時間: 96 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • 製剤: Dissolved in DMSO
  • 投薬量: ~5 mg/kg/day
  • 投与方法: Injection s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
体内 順序で溶剤を入れること:
1% DMSO+30% polyethylene glycol+1% Tween 80, pH 4
6 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC信号経路図

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA) ic50 | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)化学構造 | Trichostatin A (TSA)分子量 | Trichostatin A (TSA)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID